NEKTAR THERAPEUTICS Contracts & Agreements
166 Contracts & Agreements
- Business Finance (53 contracts)
- Business Operations (8)
- Human Resources (57)
- Intellectual Property (4)
- Mergers & Acquisitions (1)
- Real Estate (3)
- Uncategorized (40)
- Nektar Therapeutics Amended and Restated 2017 Performance Incentive Plan, as amended (Filed With SEC on August 9, 2024)
- Amendment No. 1 to Purchase and Sale Agreement, dated December 16, 2020, by and between entities managed by Healthcare Royalty Management, LLC and Nektar Therapeutics (Filed With SEC on May 10, 2024)
- Form of Pre-Funded Warrant (Filed With SEC on March 4, 2024)
- Securities Purchase Agreement, dated March 4, 2024, by and between Nektar Therapeutics and TCG Crossover Fund II, L.P (Filed With SEC on March 4, 2024)
- Letter Agreement dated as of September 6, 2023 by and between Bristol-Myers Squibb and Company and Nektar Therapeutics (Filed With SEC on November 8, 2023)
- Employment Separation and Release Agreement effective as of June 19, 2023 by and between Nektar Therapeutics and Jillian B. Thomsen (Filed With SEC on August 9, 2023)
- Nektar Therapeutics Amended and Restated 2017 Performance Incentive Plan, as amended (Filed With SEC on August 9, 2023)
- Consulting Agreement between Nektar Therapeutics and FLG Partners, LLC dated April 7, 2023 (Filed With SEC on May 10, 2023)
- Nektar Therapeutics Amended and Restated 2017 Performance Incentive Plan, as amended (Filed With SEC on August 5, 2022)
- Employment Transition, Separation and Consultation Agreement, dated as of June 29, 2022, by and between Nektar Therapeutics and John Northcott (Filed With SEC on August 5, 2022)
- Amendment No. 2 to Strategic Collaboration Agreement dated as of January 12, 2022, by and between Bristol-M (Filed With SEC on March 1, 2022)
- Nektar Therapeutics Amended and Restated 2017 Performance Incentive Plan, as amended (Filed With SEC on August 6, 2021)
- Co-Development Agreement, dated as of February 1 (Filed With SEC on February 26, 2021)
- Purchase and Sale Agreement, dated December 16, 2020, by and between entities managed by Healthcare Royalty Management, LLC and Nektar Therapeutics (Filed With SEC on February 26, 2021)
- Nektar Therapeutics Amended and Restated 2017 Performance Incentive Plan, as amended (Filed With SEC on August 7, 2020)
- Nektar Therapeutics Amended and Restated Employee Stock Purchase Plan (Filed With SEC on August 7, 2020)
- Amended and Restated Compensation Plan for Non-Employee Directors (Filed With SEC on May 8, 2020)
- Description of Securities (Filed With SEC on February 28, 2020)
- Transition, Separation and General Release Agreement, dated as of January 9, 2020, by and between Stephen K. Doberstein and Nektar Therapeutics (Filed With SEC on February 28, 2020)
- Employment Agreement effective as of December 4, 2019, by and between Nektar Therapeutics and John Northcott (Filed With SEC on February 28, 2020)
- Amendment No. 1 to Strategic Collaboration Agreement dated as of January 9, 2020, by and between Bristol-Myers Squibb and Company and Nektar Therapeutics (Filed With SEC on February 28, 2020)
- Separation, Consulting and General Release Agreement (Filed With SEC on November 7, 2019)
- Forms of Stock Option Agreement, Performance Stock Option Agreement, Non-Employee Director Stock Option Agreement, Restricted Stock Unit Agreement, Performance Restricted Stock... (Filed With SEC on March 1, 2019)
- Nektar Therapeutics Amended and Restated 2017 Performance Incentive Plan (Filed With SEC on June 27, 2018)
- Investor Agreement, dated as of February 13, 2018, by and between Bristol-Myers Squibb and Company and Nektar Therapeutics (Filed With SEC on May 10, 2018)
- Forms of Stock Option Agreement, Performance Stock Option Agreement, Non-Employee Director Stock Option Agreement, Restricted Stock Unit Agreement, Performance Restricted Stock... (Filed With SEC on March 1, 2018)
- Separation and General Release Agreement dated as of December 20, 2017, by and between Nektar Therapeutics and Ivan Gergel, M.D (Filed With SEC on March 1, 2018)
- Share Purchase Agreement dated February 13, 2018, by and between Nektar Therapeutics and Bristol-Myers Squibb Company (Filed With SEC on February 14, 2018)
- License Agreement effective as of August 23, 2017, by and between Eli Lilly and Company and Nektar Therapeutics (Filed With SEC on November 8, 2017)
- Lease Agreement dated August 4, 2017, as amended by the First Amendment to Lease dated as of August 29, 2017, by and between ARE-San Francisco No. 19, LLC and Nektar Therapeutics (Filed With SEC on November 8, 2017)
- Nektar Therapeutics 2017 Performance Incentive Plan (Filed With SEC on June 15, 2017)
- CLINICAL TRIAL COLLABORATION AGREEMENT (Filed With SEC on November 4, 2016)
- NEKTAR THERAPEUTICS 13,000,000Shares of Common Stock, $0.0001 par value per share Underwriting Agreement (Filed With SEC on October 19, 2016)
- COLLABORATION AND LICENSE AGREEMENT by and between DAIICHI SANKYO EUROPE GMBH and NEKTAR THERAPEUTICS DATE: May 30, 2016 (Filed With SEC on August 4, 2016)
- AMENDED AND RESTATED COMPENSATION PLAN FOR NON-EMPLOYEE DIRECTORS (Filed With SEC on February 29, 2016)
- NektarTherapeutics 2012Performance Incentive Plan StockOption Agreement (USOptionholders) (Filed With SEC on December 17, 2015)
- NektarTherapeutics 2012Performance Incentive Plan PerformanceStock Option Agreement (Filed With SEC on December 17, 2015)
- NektarTherapeutics 2012Performance Incentive Plan RestrictedStock Unit Agreement (Filed With SEC on December 17, 2015)
- NektarTherapeutics 2012Performance Incentive Plan PerformanceRestricted Stock Unit Agreement (Filed With SEC on December 17, 2015)
- $250,000,000 Nektar Therapeutics 7.750% Senior Secured Notes due 2020 PURCHASE AGREEMENT (Filed With SEC on October 6, 2015)
- NEKTAR THERAPEUTICS 7.75% SENIOR SECURED NOTES DUE 2020 (Filed With SEC on October 6, 2015)
- PLEDGE AND SECURITY AGREEMENT (Filed With SEC on October 6, 2015)
- NEKTAR THERAPEUTICS 2012 PERFORMANCE INCENTIVE PLAN (Filed With SEC on June 17, 2015)
- NektarTherapeutics EmployeeStock Purchase Plan Adoptedby the Board of Directors February 10, 1994 Approvedby Stockholders February 18, 1994 Amendedand Restated May 10, 2002... (Filed With SEC on June 27, 2014)
- EMPLOYMENT TRANSITION AND GENERAL RELEASE AGREEMENT (Filed With SEC on February 27, 2014)
- TERM LOAN AND SECURITY AGREEMENT among NEKTAR THERAPEUTICS, as Borrower, theGuarantors from time to time party hereto, as Guarantors, and ASTRAZENECA AB, as Agent October 7, 2013... (Filed With SEC on February 27, 2014)
- NEKTAR THERAPEUTICS 8,500,000Shares of Common Stock, $0.0001 par value per share Underwriting Agreement (Filed With SEC on January 28, 2014)
- AMENDMENT NO. 1 TO LICENSE AGREEMENT (Filed With SEC on November 7, 2013)
- NEKTAR THERAPEUTICS 2012 PERFORMANCE INCENTIVE PLAN STOCK OPTION AGREEMENT (US OPTIONHOLDERS) (Filed With SEC on March 1, 2013)
- AMENDED AND RESTATED COMPENSATION PLAN FOR NON-EMPLOYEE DIRECTORS (Filed With SEC on March 1, 2013)
- PLEDGE AND SECURITY AGREEMENT (Filed With SEC on March 1, 2013)
- NEKTAR THERAPEUTICS 12.00% SENIOR SECURED NOTES DUE 2017 INDENTURE Dated as of July 11, 2012 Wells Fargo Bank, National Association Trustee and Collateral Agent (Filed With SEC on July 11, 2012)
- PLEDGE AND SECURITY AGREEMENT (Filed With SEC on July 11, 2012)
- ESCROW AND DEPOSIT ACCOUNT CONTROL AGREEMENT among NEKTAR THERAPEUTICS, WELLS FARGO BANK, NATIONAL ASSOCIATION as Collateral Agent, and WELLS FARGO BANK, NATIONAL ASSOCIATION as... (Filed With SEC on July 11, 2012)
- $125,000,000 Nektar Therapeutics 12.000% Senior Secured Notes due 2017 PURCHASE AGREEMENT (Filed With SEC on July 10, 2012)
- NEKTAR THERAPEUTICS 2012 PERFORMANCE INCENTIVE PLAN (Filed With SEC on July 3, 2012)
- PURCHASE AND SALE AGREEMENT dated as of February 24, 2012 between NEKTAR THERAPEUTICS and RPI FINANCE TRUST (Filed With SEC on May 4, 2012)
- NEKTAR THERAPEUTICS (formerly known as Inhale Therapeutic Systems, Inc.) 2000 NON-OFFICER EQUITY INCENTIVE PLAN Adopted August 18, 1998 Amended February 23, 1999 Amended December... (Filed With SEC on February 29, 2012)
- NEKTAR THERAPEUTICS (formerly known as Inhale Therapeutic Systems, Inc.) 2000 EQUITY INCENTIVE PLAN Adopted February 10, 1994 Approved By Shareholders February 18, 1994 Amended... (Filed With SEC on February 29, 2012)
- NEKTAR THERAPEUTICS 2008 EQUITY INCENTIVEPLAN Adopted by the Board of Directors on March 20, 2008 Approved by the Shareholders on June 6, 2008 Amended by the Board of Directors on... (Filed With SEC on February 29, 2012)
- AMENDED AND RESTATED COMPENSATION PLAN FOR NON-EMPLOYEE DIRECTORS (Filed With SEC on February 29, 2012)
- Nektar Discretionary Incentive Compensation Policy (Filed With SEC on February 29, 2012)
- NEKTAR THERAPEUTICS AMENDED AND RESTATED CHANGE OF CONTROL SEVERANCE BENEFIT PLAN PLAN DOCUMENT AND SUMMARY PLAN DESCRIPTION NEKTAR THERAPEUTICS AMENDED AND RESTATED CHANGE OF... (Filed With SEC on February 29, 2012)
- NEKTAR THERAPEUTICS AMENDED AND RESTATED CHANGE OF CONTROL SEVERANCE BENEFIT PLAN PLAN DOCUMENT AND SUMMARY PLAN DESCRIPTION NEKTAR THERAPEUTICS AMENDED AND RESTATED CHANGE OF... (Filed With SEC on April 11, 2011)
- improve efficacy or safety in certain instances as a result of better pharmacokinetics, pharmacodynamics, longer half-life and sustained exposure of the drug (Filed With SEC on March 1, 2011)
- improve efficacy or safety in certain instances as a result of better pharmacokinetics, pharmacodynamics, longer half-life and sustained exposure of the drug (Filed With SEC on March 1, 2011)
- improve efficacy or safety in certain instances as a result of better pharmacokinetics, pharmacodynamics, longer half-life and sustained exposure of the drug (Filed With SEC on March 1, 2011)
- improve efficacy or safety in certain instances as a result of better pharmacokinetics, pharmacodynamics, longer half-life and sustained exposure of the drug (Filed With SEC on March 1, 2011)
- improve efficacy or safety in certain instances as a result of better pharmacokinetics, pharmacodynamics, longer half-life and sustained exposure of the drug (Filed With SEC on March 1, 2011)
- improve efficacy or safety in certain instances as a result of better pharmacokinetics, pharmacodynamics, longer half-life and sustained exposure of the drug (Filed With SEC on March 1, 2011)
- improve efficacy or safety in certain instances as a result of better pharmacokinetics, pharmacodynamics, longer half-life and sustained exposure of the drug (Filed With SEC on March 1, 2011)
- improve efficacy or safety in certain instances as a result of better pharmacokinetics, pharmacodynamics, longer half-life and sustained exposure of the drug (Filed With SEC on March 1, 2011)
- improve efficacy or safety in certain instances as a result of better pharmacokinetics, pharmacodynamics, longer half-life and sustained exposure of the drug (Filed With SEC on March 1, 2011)
- 19,000,000Shares NEKTARTHERAPEUTICS CommonStock ($0.0001par value per Share) UNDERWRITINGAGREEMENT (Filed With SEC on January 21, 2011)
- SEPARATION AND GENERALRELEASE AGREEMENT (Filed With SEC on December 30, 2010)
- NEKTARTHERAPEUTICS AMENDEDAND RESTATED CHANGE OF CONTROL SEVERANCE BENEFIT PLAN PLANDOCUMENT AND SUMMARY PLAN DESCRIPTION NEKTARTHERAPEUTICS AMENDEDAND RESTATED CHANGEOF CONTROL... (Filed With SEC on December 6, 2010)
- NektarTherapeutics EmployeeStock Purchase Plan Adoptedby the Board of Directors February 10, 1994 ApprovedbyStockholders February 18, 1994 Amendedand Restated May 10, 2002... (Filed With SEC on July 6, 2010)
- Nektar DiscretionaryIncentive Compensation Policy (Filed With SEC on March 3, 2010)
- AMENDEDAND RESTATED COMPENSATIONPLAN FOR NON-EMPLOYEE DIRECTORS (Filed With SEC on December 14, 2009)
- SEPARATION AND GENERALRELEASE AGREEMENT (Filed With SEC on November 30, 2009)
- LICENSEAGREEMENT byand between ASTRAZENECAAB and NEKTARTHERAPEUTICS DATE:September20, 2009 (Filed With SEC on November 5, 2009)
- SUBLEASE (Filed With SEC on November 5, 2009)
- improve efficacy or safety in certain instances as a result of better pharmacokinetics, pharmacodynamics, longer half-life and sustained exposure of the drug (Filed With SEC on March 6, 2009)
- improve efficacy or safety in certain instances as a result of better pharmacokinetics, pharmacodynamics, longer half-life and sustained exposure of the drug (Filed With SEC on March 6, 2009)
- improve efficacy or safety in certain instances as a result of better pharmacokinetics, pharmacodynamics, longer half-life and sustained exposure of the drug (Filed With SEC on March 6, 2009)
- improve efficacy or safety in certain instances as a result of better pharmacokinetics, pharmacodynamics, longer half-life and sustained exposure of the drug (Filed With SEC on March 6, 2009)
- improve efficacy or safety in certain instances as a result of better pharmacokinetics, pharmacodynamics, longer half-life and sustained exposure of the drug (Filed With SEC on March 6, 2009)
- improve efficacy or safety in certain instances as a result of better pharmacokinetics, pharmacodynamics, longer half-life and sustained exposure of the drug (Filed With SEC on March 6, 2009)
- improve efficacy or safety in certain instances as a result of better pharmacokinetics, pharmacodynamics, longer half-life and sustained exposure of the drug (Filed With SEC on March 6, 2009)
- improve efficacy or safety in certain instances as a result of better pharmacokinetics, pharmacodynamics, longer half-life and sustained exposure of the drug (Filed With SEC on March 6, 2009)
- improve efficacy or safety in certain instances as a result of better pharmacokinetics, pharmacodynamics, longer half-life and sustained exposure of the drug (Filed With SEC on March 6, 2009)
- improve efficacy or safety in certain instances as a result of better pharmacokinetics, pharmacodynamics, longer half-life and sustained exposure of the drug (Filed With SEC on March 6, 2009)
- improve efficacy or safety in certain instances as a result of better pharmacokinetics, pharmacodynamics, longer half-life and sustained exposure of the drug (Filed With SEC on March 6, 2009)
- BONUS AND GENERAL RELEASEAGREEMENT (Filed With SEC on January 2, 2009)
- Current assets (Filed With SEC on May 9, 2008)
- Current assets (Filed With SEC on May 9, 2008)
- NEKTAR THERAPEUTICS SEVERANCE BENEFIT PLAN (Filed With SEC on February 29, 2008)
- TERMINATION AGREEMENT AND MUTUAL RELEASE (Filed With SEC on February 29, 2008)
- EXCLUSIVE RESEARCH, DEVELOPMENT, (Filed With SEC on February 29, 2008)
- SEPARATION AND GENERAL RELEASE AGREEMENT (Filed With SEC on December 12, 2007)
- NEKTAR THERAPEUTICS, AEROGEN, INC., AND BAYER HEALTHCARE LLC CO-DEVELOPMENT, LICENSE AND CO-PROMOTION AGREEMENT AUGUST 1, 2007 (Filed With SEC on November 9, 2007)
- NEKTAR THERAPEUTICS 2000 EQUITYINCENTIVE PLAN RESTRICTED STOCK UNITAGREEMENT (Filed With SEC on November 9, 2007)
- NEKTAR THERAPEUTICS 2000 EQUITYINCENTIVE PLAN STOCK OPTION AGREEMENT (Filed With SEC on November 9, 2007)
- EMPLOYMENT TRANSITION AND SEPARATION RELEASE AGREEMENT (Filed With SEC on November 9, 2007)
- EMPLOYMENT TRANSITION AND SEPARATION RELEASE AGREEMENT (Filed With SEC on November 9, 2007)
- AMENDED AND RESTATED BUILT-TO-SUIT LEASE (Filed With SEC on November 9, 2007)
- NEKTAR THERAPEUTICS AMENDED AND RESTATED CHANGE OF CONTROL (Filed With SEC on November 9, 2007)
- Nektar Discretionary Performance-Based Incentive Compensation Policy (Filed With SEC on March 1, 2007)
- NEKTAR THERAPEUTICS (Filed With SEC on March 1, 2007)
- COMPENSATION PLAN FOR NON-EMPLOYEE DIRECTORS (Filed With SEC on February 26, 2007)
- EXHIBIT A EMPLOYEE AGREEMENT (Filed With SEC on January 9, 2007)
- SETTLEMENT AGREEMENT AND GENERAL RELEASE (Filed With SEC on August 9, 2006)
- NEKTAR THERAPEUTICS (formerly known as Inhale Therapeutic Systems, Inc.) 2000 EQUITY INCENTIVE PLAN Adopted February 10, 1994 Approved By Shareholders February 18,1994 Amended... (Filed With SEC on June 7, 2006)
- 2006 EXECUTIVE COMPENSATION PLAN (Filed With SEC on March 23, 2006)
- COMPENSATION PLAN FOR NON-EMPLOYEE DIRECTORS (Filed With SEC on March 23, 2006)
- [Nektar Letterhead] (Filed With SEC on March 16, 2006)
- NEKTAR THERAPEUTICS 2000 EQUITYINCENTIVE PLAN RESTRICTED STOCK UNIT GRANTNOTICE (Filed With SEC on March 16, 2006)
- NEKTAR THERAPEUTICS 2000 NON-OFFICER EQUITY INCENTIVE PLAN RESTRICTED STOCK UNIT GRANT NOTICE (Filed With SEC on March 16, 2006)
- NEKTAR THERAPEUTICS SEVERANCE BENEFIT PLAN (Filed With SEC on March 16, 2006)
- NEKTAR VARIABLE COMPENSATION PLAN (Filed With SEC on March 16, 2006)
- [Nektar Therapeutics Letterhead] (Filed With SEC on March 8, 2006)
- INDENTURE between (Filed With SEC on September 28, 2005)
- REGISTRATION RIGHTS AGREEMENT (Filed With SEC on September 28, 2005)
- NEKTAR THERAPEUTICS (a Delaware corporation) $275,000,000 3.25% Convertible Subordinated Notes due 2012 PURCHASE AGREEMENT (Filed With SEC on September 28, 2005)
- COMMON STOCK PURCHASE AGREEMENT (Filed With SEC on August 17, 2005)
- AGREEMENT AND PLAN OF MERGER Dated as of August 12, 2005 (Filed With SEC on August 16, 2005)
- 2005 EXECUTIVE COMPENSATION PLAN (Filed With SEC on March 21, 2005)
- 2005 COMPENSATION PLAN FOR NON-EMPLOYEE DIRECTORS (Filed With SEC on March 21, 2005)
- NEKTAR THERAPEUTICS (Filed With SEC on March 21, 2005)
- LICENSE AGREEMENT BETWEEN INHALE THERAPEUTIC SYSTEMS (Filed With SEC on March 14, 2005)
- DEVELOPMENT ANDLICENSE AGREEMENT (Filed With SEC on March 14, 2005)
- Addendum of Offer of Employment (Filed With SEC on March 14, 2005)
- NEKTAR THERAPEUTICS (formerly known as Inhale Therapeutic Systems, Inc.) 2000 NON-OFFICER EQUITY INCENTIVEPLAN Adopted August 18, 1998 Amended February 23, 1999 Amended December... (Filed With SEC on August 5, 2004)
- NEKTAR THERAPEUTICS (formerly known as Inhale Therapeutic Systems, Inc.) 2000 EQUITY INCENTIVE PLAN Adopted February 10, 1994 Approved By ShareholdersFebruary 18, 1994 Amended... (Filed With SEC on August 5, 2004)
- THE CORPORATEPLAN FOR RETIREMENTSM FIDELITY BASIC PLAN DOCUMENT NO. 02 2003 FMR Corp. All rights reserved. (Filed With SEC on August 5, 2004)
- THECORPORATEPLAN FOR RETIREMENTSM (PROFITSHARING/401(K) PLAN) A FIDELITYPROTOTYPE PLAN Non-StandardizedAdoption Agreement No. 001 For use With FidelityBasic Plan Document No. 02 (Filed With SEC on August 5, 2004)
- NEKTARTHERAPEUTICS (a Delawarecorporation) 9,500,000 Sharesof Common Stock UNDERWRITINGAGREEMENT (Filed With SEC on March 11, 2004)
- RESALEREGISTRATION RIGHTS AGREEMENT (Filed With SEC on November 3, 2003)
- PLEDGE AGREEMENT (Filed With SEC on November 3, 2003)
- EXCHANGEAGREEMENT (Filed With SEC on November 3, 2003)
- EXCHANGEAGREEMENT (Filed With SEC on November 3, 2003)
- EXCHANGEAGREEMENT (Filed With SEC on November 3, 2003)
- FIRSTSUPPLEMENTAL INDENTURE (Filed With SEC on October 20, 2003)
- PLEDGE AGREEMENT (Filed With SEC on October 20, 2003)
- EXCHANGEAGREEMENT (Filed With SEC on October 20, 2003)
- AMENDMENT NO. 1 TO EXCHANGE AGREEMENT (Filed With SEC on October 20, 2003)
- INDENTURE between NEKTARTHERAPEUTICS, asIssuer and J.P. MORGANTRUST COMPANY, NATIONAL ASSOCIATION asTrustee 3%CONVERTIBLE SUBORDINATED NOTES DUE 2010 Datedas of October 9, 2003... (Filed With SEC on October 10, 2003)
- RESALEREGISTRATION RIGHTS AGREEMENT (Filed With SEC on October 10, 2003)
- FORM OF SECURITY [FACE OF SECURITY] (Filed With SEC on October 10, 2003)
- PLEDGE AGREEMENT (Filed With SEC on October 10, 2003)
- EXCHANGEAGREEMENT (Filed With SEC on October 10, 2003)
- EXCHANGEAGREEMENT (Filed With SEC on October 10, 2003)
- AMENDMENT NO. 1 TO EXCHANGE AGREEMENT (Filed With SEC on October 10, 2003)
- AMENDMENT NO. 1 TO EXCHANGE AGREEMENT (Filed With SEC on October 10, 2003)
- NEKTAR THERAPEUTICS (a Delaware corporation) $100,000,000 3% Convertible Subordinated Notes due 2010 PURCHASE AGREEMENT (Filed With SEC on July 2, 2003)
- RESALE REGISTRATIONRIGHTS AGREEMENT among NEKTAR THERAPEUTICS, MERRILL LYNCH, PIERCE,FENNER & SMITH INCORPORATED DEUTSCHEBANK SECURITIES INC. LEHMANBROTHERS INC.... (Filed With SEC on July 2, 2003)
- INDENTURE between NEKTARTHERAPEUTICS, asIssuer and J.P. MORGANTRUST COMPANY, NATIONAL ASSOCIATION asTrustee 3%CONVERTIBLE SUBORDINATED NOTES DUE 2010 Datedas of June 30, 2003... (Filed With SEC on July 2, 2003)
- PLEDGE AGREEMENT (Filed With SEC on July 2, 2003)
- EMPLOYEERELOCATION REPAYMENT AGREEMENT (Filed With SEC on May 13, 2003)
- Addendum to Offer of Employment (Filed With SEC on May 13, 2003)
- INHALE THERAPEUTIC SYSTEMS, INC. AND AFACEQUITY, L.P. COMMON STOCK PURCHASE AGREEMENT December 6, 2002 INHALE THERAPEUTIC SYSTEMS, INC. COMMON STOCK PURCHASE AGREEMENT (Filed With SEC on March 28, 2003)
- NEKTARTHERAPEUTICS (FORMERLYKNOWN AS INHALE THERAPEUTIC SYSTEMS, INC.) SEVERANCE BENEFIT PLAN (Filed With SEC on March 28, 2003)
- NUMBER (Filed With SEC on January 23, 2003)
- INHALETHERAPEUTIC SYSTEMS, INC. AND AFAC EQUITY, L.P. COMMON STOCK PURCHASE AGREEMENT June 7, 2002 INHALETHERAPEUTIC SYSTEMS, INC. COMMONSTOCK PURCHASE AGREEMENT (Filed With SEC on November 14, 2002)
- INHALE THERAPEUTIC SYSTEMS, INC. AND AFAC EQUITY, L.P. COMMON STOCK PURCHASE AGREEMENT July 9, 2002 INHALETHERAPEUTIC SYSTEMS, INC. COMMONSTOCK PURCHASE AGREEMENT (Filed With SEC on November 14, 2002)
- CONFIDENTIAL (Filed With SEC on November 14, 2002)